<code id='734C9A9F29'></code><style id='734C9A9F29'></style>
    • <acronym id='734C9A9F29'></acronym>
      <center id='734C9A9F29'><center id='734C9A9F29'><tfoot id='734C9A9F29'></tfoot></center><abbr id='734C9A9F29'><dir id='734C9A9F29'><tfoot id='734C9A9F29'></tfoot><noframes id='734C9A9F29'>

    • <optgroup id='734C9A9F29'><strike id='734C9A9F29'><sup id='734C9A9F29'></sup></strike><code id='734C9A9F29'></code></optgroup>
        1. <b id='734C9A9F29'><label id='734C9A9F29'><select id='734C9A9F29'><dt id='734C9A9F29'><span id='734C9A9F29'></span></dt></select></label></b><u id='734C9A9F29'></u>
          <i id='734C9A9F29'><strike id='734C9A9F29'><tt id='734C9A9F29'><pre id='734C9A9F29'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:65912
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          When waiting feels immoral: Empathy in the emergency department
          When waiting feels immoral: Empathy in the emergency department

          AdobeMr.Kaneisusingonehandtoclutchtheplasticbasinintowhichheisvomitingandgesturinghellowiththeotherh

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Biotech startup Celsius cuts 75% of staff ahead of first trial start

          AdobeLaunchingyourfirstclinicaltrialisthetypeofannouncementmostbiotechexecutiveseagerlyanticipate,ho